# Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer

> **NCT06006104** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 49 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** HRS-4357 injection

## Key facts

- **NCT ID:** NCT06006104
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-30
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-10-31
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006104, "Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06006104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*